Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
Phase 3
Completed
- Conditions
- AnemiaEnd Stage Renal Disease (ESRD)
- Interventions
- First Posted Date
- 2014-10-30
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 838
- Registration Number
- NCT02278341
- Locations
- 🇧🇪
Site BE32004, Brussels, Flemish Brabant, Belgium
🇧🇪Site BE32001, Aalst, Belgium
🇧🇪Site BE32019, Antwerpen, Belgium
A Study to Evaluate the Effects of Multiple Doses of FG-4592 on the Exposure, Safety and Tolerability and Effect of Warfarin in Healthy Subjects
Phase 1
Completed
- Conditions
- Pharmacokinetics of FG-4592Healthy Subjects
- Interventions
- First Posted Date
- 2014-09-30
- Last Posted Date
- 2014-09-30
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 22
- Registration Number
- NCT02252731
- Locations
- 🇩🇪
Parexel International GmbH, Berlin, Germany
A Study to Assess the Safety, Tolerability, and Effects in and on the Body of Healthy Young and Elderly Male and Female Subjects of Ascending Multiple Oral Doses of ASP3652
Phase 1
Completed
- Conditions
- Healthy SubjectsPharmacokinetics of ASP3652Pharmacodynamics of ASP3652
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-09-18
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 101
- Registration Number
- NCT02243657
- Locations
- 🇳🇱
PRA International, Groningen, Netherlands
A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer
Phase 1
Completed
- Conditions
- Prostate CancerPharmacokinetics of DextromethorphanPharmacokinetics of Caffeine
- Interventions
- First Posted Date
- 2014-08-26
- Last Posted Date
- 2017-06-27
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 12
- Registration Number
- NCT02225093
- Locations
- 🇲🇩
Arensia, Chisinau, Moldova, Republic of
A Study to Assess the Effects of Single Ascending Doses (SAD) of ASP8477, the Effect That Food Has on the Drug, and the Interaction Between ASP8477 and Omeprazole in Healthy Postmenopausal Females and Healthy Young Vasectomized Males
Phase 1
Completed
- Conditions
- Pharmacokinetics of ASP8477Pharmacodynamics of ASP8477
- Interventions
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 72
- Registration Number
- NCT02220777
- Locations
- 🇧🇪
SGS Belgium N.V., Antwerp, Belgium
🇫🇷SGS Aster, Paris, France
A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Phase 3
Completed
- Conditions
- Clostridium Difficile-associated Diarrhea (CDAD)
- Interventions
- First Posted Date
- 2014-08-18
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 148
- Registration Number
- NCT02218372
- Locations
- 🇺🇸
Site US10015, Orange, California, United States
🇺🇸Site US10010, Chicago, Illinois, United States
🇺🇸Site US10004, Indianapolis, Indiana, United States
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease
Phase 1
Completed
- Conditions
- Chronic Kidney Disease (CKD)Pharmacokinetics of ASP8232Type 2 Diabetes Mellitus (T2DM)Healthy SubjectsPharmacodynamics of ASP8232
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 55
- Registration Number
- NCT02218099
- Locations
- 🇧🇬
Site: 35901, Sofia, Bulgaria
🇲🇩Site: 37301, Chisinau, Moldova, Republic of
🇷🇴Site: 40001, Bucharest, Romania
A Study to Assess the Interaction Between ASP1707 and Itraconazole in Healthy Female Subjects
Phase 1
Completed
- Conditions
- PharmacokineticsHealthy SubjectsDDI (Drug-Drug Interaction)
- Interventions
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2014-07-03
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 14
- Registration Number
- NCT02175407
- Locations
- 🇩🇪
PAREXEL International GmbH, Berlin, Germany
Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy SubjectsDrug-Drug Interaction (DDI)Pharmacokinetics
- Interventions
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2014-08-29
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 20
- Registration Number
- NCT02169713
- Locations
- 🇩🇪
Parexel International GmbH, Berlin, Germany
A Study to Evaluate the Dose-proportionality and Effects of FG-4592 in Healthy Young and Elderly Male and Female Subjects
- First Posted Date
- 2014-06-12
- Last Posted Date
- 2014-06-12
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 48
- Registration Number
- NCT02161796
- Locations
- 🇩🇪
Parexel International GmbH, Berlin, Germany